Eli Lilly and Company is a drug manufacturing company. The Company is engaged in the discovery, development, manufacturing, marketing, and sales of pharmaceutical products across the world. The Company's diabetes products include Baqsimi, Basaglar, Humalog, Humulin, Jardiance, Lyumjev, Trajenta and Trulicity. Its oncology products include Alimta, Cyramza, Erbitux, Retevmo, Tyvyt and Verzenio. The Company's immunology products consist of Olumiant and Taltz. Its neuroscience products include Cymbalta, Emgality, Reyvow and Zyprexa. Its other therapies consist of Bamlanivimab, etesevimab, Cialis and Forteo. The Company manufactures and distributes its products through facilities in the United States, including Puerto Rico, and about eight other countries. Its products are sold in approximately 120 countries. Its subsidiaries include Acanthas Pharma, Inc., Alnara Pharmaceuticals, Inc., ARMO Biosciences, Inc., and Avid Radiopharmaceuticals, Inc., among others.
52 Week high
52 Week low
InvestorPlace • 1 day ago • LLYImmunomics Stocks: 3 Ways to Play This Massive AI-Biotech Megatrend
The Motley Fool • 1 day ago • LLYAre Wall Street Analysts Wrong About Eli Lilly Stock?
Market Watch • 1 day ago • LLYEli Lilly, Boehringer Ingelheim's Jardiance gets FDA approval for chronic kidney disease
PRNewsWire • 1 day ago • LLYUS FDA approves Jardiance® for the treatment of adults with chronic kidney disease
Market Watch • 1 day ago • LLYEli Lilly set to dominate obesity drug market into the next decade, analysts say
Charts and pricing are provided for informational purposes only. The current market data is delayed up to 15 minutes. The accuracy of any market data displayed is not guaranteed.